Patents by Inventor Fiona Ellard

Fiona Ellard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070259400
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: April 26, 2006
    Publication date: November 8, 2007
    Applicant: Oxford BioMedica (UK) Limited
    Inventors: Alan Kingsman, Susan Kingsman, Christopher Bebbington, Miles Carrol, Fiona Ellard, Kevin Myers
  • Publication number: 20070161080
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: July 7, 2006
    Publication date: July 12, 2007
    Applicant: Oxford BioMedica (UK) Limited
    Inventors: Alan Kingsman, Susan Kingsman, Christopher Bebbington, Miles Carrol, Fiona Ellard, Kevin Myers
  • Publication number: 20060286634
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Application
    Filed: April 25, 2006
    Publication date: December 21, 2006
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Susan Kingsman, Christopher Bebbington, Fiona Ellard, Miles Carroll, Kevin Myers
  • Publication number: 20060099180
    Abstract: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable or recognising the target site.
    Type: Application
    Filed: August 16, 2004
    Publication date: May 11, 2006
    Inventors: Kyriacos Mitrophanous, Deva Patil, Alan Kingsman, Susan Kingsman, Fiona Ellard
  • Publication number: 20060014222
    Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.
    Type: Application
    Filed: November 2, 2001
    Publication date: January 19, 2006
    Inventors: Susan Kingsman, Christopher Bebbington, Miles Carroll, Fiona Ellard, Kevin Myers
  • Publication number: 20050273872
    Abstract: The present invention relates to the generation of transgenic avians and the production of recombinant proteins. More particularly, the invention relates to the enhanced transduction of avian cells by exogenous genetic material so that the genetic material is incorporated into an avian genome in such a way that the modification becomes integrated into the germline and results in expression of the encoded protein within the avian egg.
    Type: Application
    Filed: November 27, 2003
    Publication date: December 8, 2005
    Applicants: Viragen Incorporated, Oxford Biomedica (UK) LTD.
    Inventors: Helen Sang, Michael McGrew, Adrain Sherman, Karen Jervis, William Stimson, Kyriacos Mitrophanous, Fiona Ellard, Alan Kingsman
  • Publication number: 20050106732
    Abstract: Provided is the use of a viral vector system to transduce/infect a target adipose tissue site. Also provided is a method of treating and/or preventing a disease in a subject and use of a viral vector system in the manufacture of a pharmaceutical composition to transduce/infect a target adipose tissue site wherein the disease is associated with a derangement in the metabolism of adipose tissue.
    Type: Application
    Filed: October 20, 2003
    Publication date: May 19, 2005
    Inventors: Susan Kingsman, Kyriacos Mitrophanous, Fiona Ellard
  • Publication number: 20050032216
    Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use of the vector is capable of delivering the NOI and/or the POI to the tumor.
    Type: Application
    Filed: February 25, 2004
    Publication date: February 10, 2005
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Susan Kingsman, Christopher Bebbington, Fiona Ellard, Miles Carroll, Kevin Myers